The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | BMT CTN 1302: maintenance ixazomib following alloHCT in patients with high-risk myeloma
Taiga Nishihori, MD, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the results from the Phase II BMT CTN 1302 trial (NCT02440464) of maintenance ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Fludarabine, melphalan and bortezomib were administered as a conditioning treatment and 12 rounds of ixazomib or placebo maintenance were administered after transplant. Dr Nishihori reports no significant progression-free survival (PFS) or overall survival (OS) between the ixazomib and placebo groups. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Taiga Nishihori, MD has received research support from Novartis and Karyopharm.
